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ABSTRACT
Many men with Cystic Fibrosis (CF) are infertile; however, few studies
have evaluated fertility outlook of men with CF since the advent of modulator
therapy. As predicted survival and quality of life improve, family planning is an
area of increased interest for the CF community. The current study surveyed
men with CF to explore their outlook on fertility, family planning, and birth control
use with the option to receive a home fertility test and follow-up interview with
study staff.
Seventy-five men with CF completed the survey and 53 (71%) believed
they were likely infertile. Most recalled learning about infertility between age 1020 years and from a healthcare provider. Forty participants (53%) reported a
previous clinical sperm count, with 27 (68%) reporting infertility. Four participants
completed at-home fertility tests, all of which were negative. These participants
found home testing valuable and easy to complete.
Seventeen participants (23%) indicated they had a child through various
means: biological, donor conceived, adopted, or stepchild. Most participants
(65%) indicated they wanted a child in the future. Men who have taken
modulators were significantly more likely to desire a child in the future than those
who have not (77% versus 53%), and to feel that they would enjoy parenting a
child (87% versus 67%).
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Using condoms for pregnancy and/or sexually transmitted infection
prevention at any time was reported by most heterosexual participants (52/70,
74%). However, some participants (39/70, 56%) reported not feeling obligated to
use birth control due to the likelihood of infertility.
Rates of known or assumed CF related male infertility are lower in this
cohort than expected. Our findings highlight opportunities for improved fertility
education including family building options, safe sex practices, and access to
semen analysis. Preliminary data support potential utility of home semen
analysis, which should be explored further in future research.
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CHAPTER 1
BACKGROUND
Cystic Fibrosis (CF) remains one of the most commonly diagnosed
recessive genetic disorders in the United States (Scotet et al., 2020). Although
previously lethal in childhood, many more individuals are living into their adult
years, with a median predicted survival of 59 years in 2020 (Cystic Fibrosis
Foundation [CFF], 2021). This is a striking improvement over previous decades
and represents the fruition of lifetime work and advocacy of many researchers,
doctors, healthcare professionals and families. As the medical world has
developed more effective methods of treating the most significant morbidities
associated with CF and treatments to address the underlying genetic causes of
CF, people with CF are able to achieve numerous lifetime goals. For men with
CF who desire to become a father, accomplishing this goal may be complicated,
as many men with CF experience infertility (McBride et al., 2021). Although
assisted reproductive technology may allow some males with infertility to father
pregnancies, barriers may exist between men with CF and access to optimal
fertility counseling and testing. Our research aimed to understand the outlook on
fertility, family planning, birth control, and contributing factors for men with CF.
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1.1 Cystic Fibrosis
CF is a complex, multisystem disease that affects the respiratory,
digestive, reproductive, and other systems. CF is a single gene, autosomal
recessive disorder first described in 1938. The birth incidence of CF has been
recently reported to be 1 in 4,000 in the US population, though incidence varies
significantly among ethnic groups and is highest in those of Northern European
descent (Scotet et al., 2020). In 1989, the cystic fibrosis transmembrane
conductance regulator (CFTR) gene was discovered and the most common
CFTR variant- F508del- was described in addition to other variants that were
thought to convey residual function in some body systems (Kerem et al., 1989).
People affected by CF experience negative effects caused by a thick mucus
lining in these tissues which is typically controlled by the body via chloride
transport across epithelial cell membranes via the CFTR protein. When chloride
is transported across the cell membrane, water molecules also move across the
cell membrane in the same direction by way of diffusion or osmosis. Therefore,
the CFTR protein also plays an integral role in fluid secretion.
1.1.1 Lung Manifestations
Lung disease is one of the most burdensome symptoms of CF and is
recognized as the most common cause of mortality in CF patients (Dinwiddie,
2000). Demise is often the last domino to fall in a chain of pulmonary events that
originates from the basic defect in CFTR. The viscosity of the mucus lining in the
lungs inhibits the function of cilia that are typically responsible for moving mucus
up the respiratory tract. This mucus also traps bacteria and other pathogens
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within the lungs, leading to recurrent infections and, secondarily, chronic lung
inflammation. Together, these factors lead to drastically worsening lung function
over a patient's lifetime. Commonly, individuals with CF experience a steep
decline in lung function from ages 6 to 30 years which is followed by a long
period of plateau (Earnest et al., 2020). However, this is variable between
individuals, even among those with the same genotype.
Individuals affected by CF are offered a wide range of interventions to help
ease pulmonary symptoms and often employ many of them in combination.
Prophylactic antibiotics help to reduce the risk of bacterial colonization. In the
case that a bacterial infection is diagnosed, oral, inhaled, and intravenous
antibiotics are used as treatments. Airway clearance is also a main goal of
treatment. Saline nebulizer treatments, breathing techniques, percussion
therapy, and special medical devices that change the amount of air pressure
inside the lungs are all utilized to clear mucus from the respiratory system.
Individuals with CF and their caregivers often spend more than an hour of every
day on airway clearance and nebulizer treatments (Johns Pool, 2019). As lung
function diminishes, lung transplant is a surgical treatment option that is pursued
by some patients with CF, but many obstacles exist.
1.1.2 Pancreatic Manifestations
The pancreas is also greatly impacted by CF. Typical pancreas function
involves secreting digestive enzymes into the duodenum. Here, these enzymes
work to break down nutrients in food. Because of the lack of water in the
digestive secretions, pancreatic enzymes are three times the concentration and
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much thicker in CF as they would be in an unaffected individual (Kelly and
Buaxbaum, 2015). Thick secretions cause blockages in pancreatic ducts, which
interfere with the enzymes exiting the pancreas. Instead, these enzymes build up
within the pancreas and cause inflammation (Kelly and Buaxbaum, 2015). This
progressive damage may lead to pancreatitis, pancreatic insufficiency, and CF
related diabetes mellitus (CFRD). Pathogenicity within the pancreas is followed
by several other possible complications along the digestive tract and related
organs. Patients with CF also struggle with malabsorption, partially due to the
lack of pancreatic enzyme to aid in digestion and partially due to the thick mucus
lining in the intestines that makes absorption of nutrients inefficient (CFF).
Achieving and maintaining a healthy weight can be difficult for many people
affected by CF (CFF).
An appropriate diet is also a focus of CF management (Stallings et al.,
2008). Nutritionists and dieticians are often specifically trained on the needs of
patients with CF. Eating a diet that is high in protein, calories, and salt is often
necessary for patients with CF to maintain their health (Stallings et al., 2008).
Additionally, taking a calculated dose of pancreatic enzymes orally before every
meal helps with absorption of the food that is consumed (Borowitz et al., 1995).
Because intake needs can be so high, some individuals with CF will get a
gastrostomy tube to make consuming enough calories more convenient.
1.1.3 Sweat Gland Manifestations
One of the earliest signs of CF recognized by parents of infants diagnosed
with CF is often a salty taste when a baby is kissed. This can be striking as
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individuals with CF have three to five times more salt in their sweat than people
who do not have CF (Quinton, 2007). This is again due to the basic defect in
CFTR. Sweat is typically secreted as a hypertonic solution of water and salt, and
then partially reabsorbed to create a hypotonic solution. Sodium and chloride are
reabsorbed with a small amount of water before sweat reaches the skin’s
surface. However, in CF, this cellular transport cannot take place as it should.
This leads to high levels of salt being present on the skin’s surface. This is one
reason for dieticians recommending high levels of salt consumption for their
patients. Replenishing lost salt is vital for maintaining electrolyte balance
throughout the body. This pathognomonic sign of CF has also become one of the
gold standards for diagnosis.
1.1.4 Reproductive Manifestations
CF affects fertility and reproduction in individuals of both sexes (Amaral et
al., 2020). Although females typically have an intact reproductive tract, factors
like secondary amenorrhea, generally poor health, and thick cervical mucus can
make becoming pregnant and carrying a pregnancy to term difficult (Ahmed et
al., 2013). However, more women with CF than ever are becoming mothers with
advances in healthcare. Conversely, many males with CF are not fertile.
Although they produce sperm, many males are born with a condition known as
congenital bilateral absence of the vas deferens (CBAVD) (Barreto et al., 1991).
CBAVD cannot typically be accurately diagnosed using a physical exam and is
generally diagnosed using ultrasound, but surgical methods of diagnosis are
equally reliable (Lin & Huang, 2020). The vas deferens is a duct that carries
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sperm from the testis, where it is produced, to the urethra, where it can then exit
the body. Without the vas deferens, natural conception is impossible. However,
with advances in reproductive technology, sperm retrieval and intracellular
insemination is now possible and allows men with CBAVD to become biological
fathers (McBride et al., 2021).
Ultimately, CF is a disease that affects many different body systems and a
person’s quality of life. Some of these factors are difficult to measure, especially
because changes in available treatments are happening so quickly. In 2020, the
median predicted survival of a person with CF was 59 years (CFF, 2021). This
represents a significant increase in life expectancy over the last several decades.
Individuals with CF are living longer, creating new challenges to ensure that
people in this community are living lives that they find personally fulfilling; for
some, this includes becoming a parent.
1.2 Diagnosing Cystic Fibrosis
In the United States, all 50 states and the District of Columbia include CF
on the newborn screening panel. Newborn screening is a panel of tests designed
to detect treatable disorders that lead to serious health problems in childhood. To
screen for CF, blood spots are used to test for high levels of immunoreactive
trypsinogen (IRT). IRT is a protein that is produced in the pancreas and can be
increased in a newborn for many reasons, not just the presence of CF. For this
reason, this test is only considered a screening and must be followed by other
tests in order to make a diagnosis of CF. In some cases of high IRT levels, a
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genetic test will also be performed on the blood spot to detect common variants
in CFTR.
There are over 2,000 known variants in CFTR. Sequencing and
deletion/duplication analysis of the CFTR gene can be useful in diagnosis and
predicting some phenotypic features of CF. However, the gold standard of
diagnosis remains the Quantitative Pilocarpine Iontophoresis Sweat Test (sweat
test) (Farrell et al., 2017). Any sweat test that is performed correctly and yields a
result of 60 mmol/L or greater of chloride in sweat secretions is indicative of a CF
diagnosis. Those between 30 and 59 mmol/L of chloride detected in a sweat test
must undergo CFTR genetic analysis in order for a diagnosis to be made.
Although many children with CF are now diagnosed at birth, individuals with nonclassic CF are commonly diagnosed in adulthood.
1.3 Genetic Mechanism of Cystic Fibrosis
Homozygous or compound heterozygous pathogenic variants in the CFTR
gene alter the quantity and/or function of CFTR protein and reduce transport of
chloride, resulting in accumulation of thick dehydrated mucus. Genetic variants
that cause CF are generally categorized into five variant classes (Veit et al.,
2016). These variants in the CFTR gene cause various problems with the
resulting protein including production, processing, gating, conduction, and
quantity differences; these are known as classes 1, 2, 3, 4, and 5, respectively
(Veit et al., 2016).
The most common pathogenic CFTR variant is F508del, which is a class 2
or processing variant (Veit et al., 2016). Class 1 and 2 variants result in little to no
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functional CFTR protein in the cell; however, CFTR modulators are highly
effective in restoring some functional CFTR protein for select class 2 variants,
including F508del (Veit et al., 2016). Class 3 variants are known as gating
defects and result in a nonfunctional CFTR protein at the cell surface. Without a
CFTR modulator, class 3 mutations result in a classic CF phenotype; however, a
robust response to a CFTR potentiation is seen for most class 3 variants,
including G551D (Veit et al., 2016). Classes 4 and 5 result in less effective and/or
less abundant CFTR channels at the cell surface (Veit et al., 2016). These
variants result in reduced transmembrane conductance, but there is some
residual function. As such, they are commonly referred to as “residual function”
variants (Veit et al., 2016). Veit et al. (2016) reported that individuals with CF
involving at least one residual function variant often have milder phenotypes
including intact pancreatic function, later age at diagnosis prior to newborn
screening, and lower sweat chloride than peers with two class 1-3 variants (Veit
et al., 2016). Residual function variants are also highly responsive to CFTR
modulator therapy. Because there are many different allele combinations, the
pathogenicity of CF can vary greatly among genotypes and even among
individuals with the same genotype (Veit et al., 2016).
Before the advent of modulators, CF treatment only addressed the
symptoms of the disease rather than the underlying cause. Now, there are two
categories of modulators (potentiators and correctors) and each works in a
different way. These modulators treat the specific defect of the CFTR protein.
Potentiators increase the activity of CFTR channels that are already on the
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surface of cells. Correctors assist in the folding of the CFTR protein so that it is
more likely to reach the surface of the cell and carry out its intended function.
Because of their differing modes of action, different modulators work for different
CFTR variants (Cuevas-Ocana et al., 2020). In 2012, the first CFTR modulator,
ivacaftor, was approved in the US by the Food and Drug Administration (FDA) for
qualified people with CF (Van Goor et al., 2014). Ivacaftor is a potentiator and is
now approved for children older than 6 months of age with a gating mutation.
Lumacaftor, a corrector, was introduced shortly after (Brewington et al., 2016).
Additional correctors, tezacaftor and elexacaftor, are also available on the market
and work similarly to lumacaftor. These drugs can be taken in combination in
order to further facilitate CFTR protein function and thereby improve lung function
as well as other morbidities associated with CF. A triple combination of
elexacaftor, tezacaftor, and ivacaftor was first approved for use in the US in
2019. This drug, sold under the name Trikafta®, is now approved for use in
children 6 years old and older and is applicable to the largest number of
individuals with CF when compared to any other modulator (Middleton et al.,
2019). For many patients, modulators have improved their quality of life and
reduced many of CF’s associated symptoms.
1.4 CFTR Expression Throughout Human Development and
Spermatogenesis
The CFTR protein is expressed and specifically regulated in the apical
membrane of exocrine epithelial cells of adults and children, and during key
stages of fetal development. CFTR transcripts have been documented in the
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developing pancreas, liver, kidneys, intestines, airways, epididymis, and vas
deferens throughout fetal development (Tizzano et al., 1993). In contrast with the
male reproductive tract, female fetuses with CF have detectable levels of CFTR
mRNA in the last trimester of development (Tizzano et al., 1993). This may
partially explain why fertility is more likely to remain intact for females with CF
(Amaral et al., 2020).
Regarding males with CF, there are two main hypotheses as to the
mechanism in which CBAVD occurs (Tizzano et al., 1993). The first is that there
is a morphogenetic defect during development. Because CFTR expression is
substantially lower in the unaffected male reproductive system than in other
organs of an unaffected individual, it is thought that the development of the
epididymis and vas deferens may have an increased sensitivity to CFTR
dysfunction. However, the presence of normal ureters indicates that Wolffian
ducts are functional during early development. Interestingly, typically functioning
portions of the male genital tract are observed more frequently in newborns
affected by CF when compared to their older counterparts. This suggests that
previously normal anatomy may degenerate. The second hypothesis suggests
that the male reproductive tract atrophies due to blockage caused by abnormal
secretions (Tizzano et al., 1993).
Additionally, the CFTR gene is expressed during all stages of
spermatogenesis and at its peak in round spermatids (Trezise et al., 1993). It is
thought to aid in nuclear condensation and cytoplasmic volume reduction at the
active transcription and transcriptional cessation stages of spermatogenesis
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(Teixeira et al., 2013). The role of CFTR in spermatogenesis is not fully
understood but is suspected to contribute to fertility status.
Typically, males with CF are counseled on fertility data that suggest only 2
to 3% of men with CF are fertile (Jarzabek et al., 2004). This data has been
collected over decades of research, but very few studies have focused
specifically on fertility as it relates to genotype. However, there is preliminary,
unpublished data from the Medical University of South Carolina Cystic Fibrosis
Center to suggest that fertility rates might be higher in men with residual function
mutations when compared to men with classic CFTR mutations (Foil, 2021).
1.5 Fatherhood in The Context of Cystic Fibrosis
Becoming a father with CF is undoubtedly a unique experience but it is
becoming increasingly more common. Limited studies have been completed that
explore the experience of fathers with CF and those studies that have been
completed are contradictory. One study of 22 men found that men with CF may
experience rapidly declining health within 2 years of the birth of their first child
(Bianco et al., 2019). This study excluded men who were on modulators or
started modulators during their study and used data collected about men who
fathered children from 1996 to 2018. However, a previously published study
found that men with CF who are fathers did not have significantly different health
statuses when compared to men with CF who were not fathers (Duguépéroux et
al., 2006). Both of these studies either excluded participants who were on
modulators or were completed prior to the introduction of modulators. Another
study found that better or worse lung function was not significantly related to the
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importance placed on having children in the future; however, men with better
lung function had more difficulty coming to terms with their infertility (Fair et al.,
2000).
Although there is an abundance of research about the psychosocial
implications for children of parents with chronic diseases, to our knowledge there
is no literature currently published about the psychosocial implications of having
a parent with CF, specifically. The results of the studies that exist are also
discrepant. In a systematic review of studies on children who have parents with
chronic illnesses, it was reported that, although some studies have found that
having a parent with a chronic illness may be beneficial in some ways, others
found that the role reversal often seen in these families is harmful to a child’s
emotional development (Chen, 2017).
As children with CF become adults, it does not seem that their desire to
have children is any less than their typical counterparts. In a survey of 94
Australian men affected by CF, 84% of them wanted to have a child (Sawyer et
al., 2005). This same survey found that 17 of the 94 participants were already
fathers: one by natural conception and six others via micro-epididymal sperm
aspiration. The remaining ten were fathers via sperm donation or stepchildren. A
study published in 2000 and completed in Scotland demonstrated that 85% of
male respondents with CF felt that having a child was important to them now or
would be within 10 years (Fair et al., 2000). All 22 men in Bianco et al.’s (2019)
study were fathers via either natural conception or micro-epididymal sperm
aspiration.

12

1.6 Counseling on Male Fertility and Birth Control Practices
CBAVD is the main cause of infertility in men with CF and is also the
cause of infertility in 2% of infertile men in the absence of other CF features (de
Souza et al., 2018). CBAVD is permanent and cannot be surgically repaired.
However, some men with CBAVD can biologically father children with the help of
assisted reproductive technologies, though barriers to accessing such
technologies exist. In addition to obstructive azoospermia, there are other
documented differences in the ejaculate of men with CF when compared to
unaffected men (McBride et al., 2021; Smith, 2010). Therefore, as in all males,
the presence of sperm alone is not a guarantee of fertility. In all men, sperm
concentration, motility, morphology, and seminal volume are related to fertility.
These factors may change over a male’s lifetime. Most of these measures
decrease over time; over a male’s lifetime, fertility is not stagnant, and changes
are likely (Harris et al., 2011). A fertility work-up that indicates intact fertility at
any given time may not predict future fertility; likewise, a negative fertility work up
does not indicate that a man was never fertile.
Fertility not only impacts steps that must be taken to conceive a
pregnancy, but also choices that may be made to prevent undesired
pregnancies. In one study of health professionals caring for adolescent males
with CF, all respondents reported that they discuss infertility with their patients;
however, only 38% discuss the importance of using condoms when sexually
active (Sawyer et al., 2001). The effects of this may be reflected in a survey of
men with CF in which 30% of respondents reported assuming they did not need
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to use a condom (Sawyer et al., 2005). Rates of condom usage are known to
vary by demographic factors and relationship status and may be lower in the CF
population than the general population based on the assumption of infertility
(Reece et al., 2010).
1.7 Male Outlook on Infertility
The majority of studies on infertility outlook focus on women, both in the
general population and in cases of CF. However, studies have shown that
infertility is no less distressing for men than it is for women (Fisher and
Hammarberg, 2012). In fact, Fair et al. (2000) discovered that men with CF are
more likely to desire a child than women with CF; 85% of men felt having a child
in the future was important compared to 72% of women (Fair et al., 2000). In
couples affected by infertility, both partners were more likely to experience
negative emotions and heightened anxiety. However, these studies were all
completed after a person learned of infertility, generally due to the inability to
conceive a child. Few studies have been done to evaluate the outlook and
attitude of men with probable infertility prior to attempts at conception, though
some specifically focusing on men with CF exist (Fair et al., 2000; Sawyer et al.,
2005).
A study of 94 Australian men with CF found that 50% of participants were
upset when they learned about fertility problems (Sawyer et al., 2005). In the
same study, 42% of participants reported that infertility had become a greater
problem over time and 22% felt that infertility had affected their personal
relationships. Sawyer et al. (2005) reported that the timing and educator also
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affected a patient’s initial reaction to information about infertility. Men who
learned of infertility from an information source other than the one they indicated
as their preference had a more negative reaction to the information. Of note, men
reported several different preferred sources of education, and this is likely based
on the individual person (Sawyer et al., 2005).
A study of 116 Scottish men with CF also examined male education on
infertility in males (Fair et al., 2000). Only men were presented with survey
questions specifically about male fertility counseling. The men in this study
reported various ages and sources of education when asked how they learned
about infertility. Importantly, when asked how they felt when they learned about
infertility, respondents most commonly indicated that they felt “shocked” (40%),
“bewildered” (24%), and “angry” (19%) (Fair et al., 2000). Only 24% of men
reported feeling “not bothered” when they learned of infertility, regardless of age
or education source (Fair et al., 2000). Overall, Fair et al. (2000) concluded that
fertility counseling should begin in early adolescence and felt that it was the
responsibility of the CF center to offer information about infertility to their patients.
Although both of the above publications offer important background on the
outlook of fertility in men with CF, they were both completed prior to the advent of
modulator therapy and outside of the US (Fair et al., 2000; Sawyer et al., 2005).
It is reasonable to hypothesize that improvements in quality of life and increase in
life expectancy due to modulator therapy may increase the desire to have
children and therefore lead to a negative reaction to probable infertility.
Additionally, sex education for adolescents varies around the world (Lameiras-
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Fernándex et al., 2021). These differences may influence attitudes of the studied
population and necessitate a closer look at a US focused population.
1.8 Spermcheck® Fertility Home Test for Men
The SpermCheck® Fertility Home Test for Men (SCFT) was approved for
home use by the FDA in 2010 (Chan, 2010). The SCFT is a rapid qualitative
immunodiagnostic home test that detects the presence of sperm in semen.
Sperm are detected using antibodies against sperm acrosome-specific protein
analyte SP10. This test underwent validation through a study that found it to be
96% accurate at detecting normal sperm count (greater than or equal to
20,000,000 sperm/mL), oligozoospermia (between 5,000,000 and 20,000,000
sperm/mL), and severe oligozoospermia (less than 5,000,000 sperm/mL) when
used correctly (Chan, 2010). The originally marketed test consisted of two
immunochromatic strips in a single cassette and is intended to be read visually.
One strip gave a positive result if sperm concentration is 20,000,000 sperm/mL
or greater (normal), and the other strip gave a positive result at 5,000,000
sperm/mL and above (oligospermia). The presence of no test lines on the
cassette after proper use indicated severe oligozoospermia (less than 5,000,000
sperm/mL) or azoospermia (no sperm present in the ejaculate). Because CBAVD
results in azoospermia, this test was expected to perform particularly well in
detecting the type of infertility most common in CF. The SCFT is now sold as a
single cassette that includes only one immunochromatic strip. This functions
identically to the strip on the original test that detected sperm at a 20,000,000
sperm/mL concentration. Meaning, the currently marketed SCFT can only detect
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normal sperm count and lower than expected sperm count; not distinguishing
between oligospermia and azoospermia.
1.9 Rationale
CF continues to be among the most common serious autosomal recessive
conditions. The birth incidence of CF has been recently reported as 1 in 4,000 in
the US population, though incidence varies significantly among ethnic groups
and is highest in those of Northern European descent (Scotet et al., 2020).
Further, improved CF testing, including newborn screening and CFTR gene
sequencing, have enabled clinical recognition of a broader phenotypic range of
CF and CFTR-related disorders, where milder cases, often involving residual
function variants, may have been missed in the past (Scotet et al., 2020). With
the advent of highly effective modulator therapy and other treatment advances,
more than half of people with CF are now adults and routinely reach ages that
they may become sexually active and consider starting a family (CFF, 2021; Hull
& Kass, 2000). Increase in lifespan and improved quality of life emphasize the
need for fertility counseling and work-up to become accessible for all interested
individuals. This information will enable informed decision making about sexual
and reproductive health.
Further investigation into the experiences of men with CF is needed in
order to optimize fertility counseling and create specific suggestions for how
adolescents may be educated regarding fertility. This study provided an updated
and more culturally focused evaluation of the perspectives and outlooks on
fertility of men with CF in the context of their previous education on fertility.
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Identifying common feelings and beliefs held by men with CF about birth control
and potential fatherhood may help healthcare providers deliver more focused
counseling pertaining to concerns about fertility. This may improve overall quality
of life for these individuals and families, as well as benefit the CF community as a
whole.
There is also a need for more research on experiences with clinical fertility
testing, specifically for men with CF who are interested in learning their fertility
status. It is our hope to further illustrate the need for fertility testing in all men with
CF who are interested in learning their fertility status. Personalized fertility
information can not only influence logistical choices when it comes to planning for
the future, but may also resolve feelings of uncertainty about fertility for men with
CF. In the current study, information regarding how men feel about their fertility
status when they have individualized information was gathered. Gaining insight
on possible changes in each participant’s perspective on fertility and family
planning, especially if they receive results that confirm their previously assumed
fertility status, will contribute to the CF community by adding to the body of
evidence that supports providing more options for fertility testing. Because of the
diversity in mutation status and combinations of mutations, data gathered on
some men with CF may not be useful for all men with CF. This study could also
provide methodology to support more extensive future research into fertility rates
among men with CF, including those with residual function variants, specifically.
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1.10 Purpose
The current study aimed to evaluate perceptions of fertility, outlook on
future children, and birth control practices in men with CF. Perceptions of fertility
may influence sexual health practices, relationships, and family planning of adult
men with CF who have been previously counseled about infertility in males with
CF. Previous studies have closely evaluated attitudes of men with CF
surrounding fertility, fatherhood, and condom usage (Fair et al., 2000; Sawyer et
al., 2005). However, with profound developments in treatment, a change in these
attitudes is possible. Additionally, family planning and fertility outlook both have
large cultural influences that may be unique in specific countries; both of the
above studies were completed outside of the US. The current study utilized an
online survey, distributed through Facebook groups, in order to evaluate the
previous counseling that men with CF received regarding fertility and their
subsequent perception and outlook on family planning. Demographic information,
CF history, previous education on infertility, current number of children, and
desire for a child in the future were evaluated. Perceptions of fertility status,
feelings of anxiety and embarrassment, as well as birth control practices were
also analyzed.
Additionally, a second part of the study evaluated participant experience
using a SCFT and compared fertility outlook before and after receiving results
from the SCFT. This FDA approved at-home semen analysis kit provided them
with information about sperm count in the privacy of their own home. A short
phone interview after reading their results was conducted to collect information
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about their results and evaluate if these results change their perceptions of their
fertility. Additionally, ease of use of at-home semen analysis was examined in
this select group of participants in order to assess the feasibility and patient
perceptions of home fertility testing for men with CF.
1.11 Study Design
The current study utilized a mixed-methods approach to examine current
perceptions and outlook on fertility, family planning, and birth control use in men
with CF. An online survey was distributed through various Facebook groups. This
survey collected information regarding demographics, CF history, previous
fertility education, number of current children, desire for future children, and
outlook on fertility and birth control use. At the conclusion of the survey,
participants were invited to participate in part two of the study. In part two of the
study, participants were provided with a SCFT to complete, and a phone
interview followed. The phone interview was used to determine potential fertility
in the participants, to evaluate any possible changes in fertility outlook based on
their results, and ease of use of the SCFT for this study population.
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CHAPTER 2
INFERTILITY EDUCATION FOR MEN WITH CYSTIC FIBROSIS AND ITS
EFFECTS: OUTLOOKS ON FERTILITY AND BIRTH CONTROL1

______________________
1Szczepanski,

A., Vincent, V., Foil, K., & Christon, L. To be submitted to Journal

of Genetic Counseling
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2.1 Abstract
Many men with Cystic Fibrosis (CF) are infertile; however, few studies
have evaluated fertility outlook of men with CF since the advent of modulator
therapy. As predicted survival and quality of life improve, family planning is an
area of increased interest for the CF community. The current study surveyed
men with CF to explore their outlook on fertility, family planning, and birth control
use with the option to receive a home fertility test and follow-up interview with
study staff.
Seventy-five men with CF completed the survey and 53 (71%) believed
they were likely infertile. Most recalled learning about infertility between age 1020 years and from a healthcare provider. Forty participants (53%) reported a
previous clinical sperm count, with 27 (68%) reporting infertility. Four participants
completed at-home fertility tests, all of which were negative. These participants
found home testing valuable and easy to complete.
Seventeen participants (23%) indicated they had a child through various
means: biological, donor conceived, adopted, or stepchild. Most participants
(65%) indicated they wanted a child in the future. Men who have taken
modulators were significantly more likely to desire a child in the future than those
who have not (77% versus 53%), and to feel that they would enjoy parenting a
child (87% versus 67%).
Using condoms for pregnancy and/or sexually transmitted infection
prevention at any time was reported by most heterosexual participants (52/70,
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74%). However, some participants (39/70, 56%) reported not feeling obligated to
use birth control due to the likelihood of infertility.
Rates of known or assumed CF related male infertility are lower in this
cohort than expected. Our findings highlight opportunities for improved fertility
education including family building options, safe sex practices, and access to
semen analysis. Preliminary data support potential utility of home semen
analysis, which should be explored further in future research.
2.2 Introduction
With a birth incidence reported to be 1 in 4,000, Cystic Fibrosis (CF)
remains one of the most diagnosed recessive genetic disorders in the United
States, although incidence varies significantly among ethnic groups (Scotet et al.,
2020). CF is a complex, multisystem disease that affects the respiratory,
digestive, reproductive, and other systems caused by the cystic fibrosis
transmembrane conductance regulator (CFTR) gene (Kerem et al., 1989). Many
more individuals with CF are living into their adult years, with a median predicted
survival of 59 years in 2020 (CFF, 2021). This is a striking improvement over
previous decades and represents significant improvements in medical
interventions and support developed for people with CF.
As the medical world has developed more effective methods of treating
the most significant morbidities associated with CF, as well as treatments to
address the underlying genetic causes of CF, people with CF are able to achieve
numerous lifetime goals. For men with CF who desire to become a father,
accomplishing this goal may be complicated, as many men with CF experience
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infertility (McBride et al., 2021). Although men with CF produce sperm, many are
born with a condition known as congenital bilateral absence of the vas deferens
(CBAVD) (Barreto et al., 1991). This is the main cause of infertility in men with
CF and cannot be surgically repaired (de Souza et al., 2018). CBAVD is a form of
obstructive azoospermia. Typically, CBAVD cannot be accurately diagnosed
using a physical exam and is generally diagnosed using ultrasound (Lin &
Huang, 2020).
Without the vas deferens, natural conception is impossible. However, with
advances in reproductive technology, sperm retrieval and intracellular
insemination is now possible and allows men with CBAVD to become biological
fathers (McBride et al., 2021). Additionally, alternative family building options,
such as adoption and sperm donation, may allow some males with CF to
experience fatherhood. Despite all of these options, barriers may exist between
men with CF and access to optimal fertility counseling and testing.
The majority of studies on infertility outlook focus on women, both in the
general population and in cases of CF. However, studies have shown that
infertility is no less distressing for men than it is for women (Fisher and
Hammarberg, 2012). In fact, Fair et al. (2000) discovered that men with CF are
more likely to desire a child than women with CF; 85% of men felt having a child
in the future was important compared to 72% of women. In a survey of 94
Australian men affected by CF, 84% of them wanted to have a child (Sawyer et
al., 2005). This same survey found that 17 of the 94 participants were already
fathers: one by natural conception and six others via micro-epididymal sperm
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aspiration. The remaining ten were fathers via sperm donation or stepchildren.
Although few studies have been done to evaluate the outlook and attitude of men
with known probable infertility prior to attempts at conception, some specifically
focusing on men with CF exists (Fair et al., 2000; Sawyer et al., 2005).
Sawyer et al. (2005) found that 50% of participants were upset when they
learned about fertility problems. In the same study, 22% of participants felt that
infertility had affected their personal relationships. Sawyer et al. (2005) reported
that the timing and educator also affected a patient’s initial reaction to information
about infertility. Men who learned of infertility from an information source other
than the one they indicated as their preference had a more negative reaction to
the information. Of note, men reported several different preferred sources of
education (i.e., medical professional and family), and this is likely based on the
individual person (Sawyer et al., 2005).
A study of 116 Scottish men with CF also examined male education on
infertility (Fair et al., 2000). Men were presented with survey questions
specifically about male fertility counseling. The men in this study reported various
ages and sources of education when asked how they learned about infertility.
Importantly, when asked how they felt when they learned about infertility,
respondents most indicated that they felt “shocked” (40%), “bewildered” (24%),
and “angry” (19%) (Fair et al., 2000). Only 24% of men reported feeling “not
bothered” when they learned of infertility, regardless of age or education source
(Fair et al., 2000). Overall, Fair et al. (2000) concluded that fertility counseling
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should begin in early adolescence and felt that it was the responsibility of the CF
center to offer information about infertility to their patients.
Fertility not only impacts steps that must be taken to conceive a
pregnancy, but also choices that may be made to prevent undesired
pregnancies. In one study of health professionals caring for adolescent males
with CF, all respondents reported that they discuss infertility with their patients;
however, only 38% discuss the importance of using condoms when sexually
active (Sawyer et al., 2001). The effects of this may be reflected in a survey of
men with CF in which 30% of respondents reported assuming they did not need
to use a condom (Sawyer et al., 2005).
Although the above publications offer important background on the outlook
of fertility in men with CF, they were completed prior to the advent of modulator
therapy and those that surveyed patients took place outside of the US (Fair et al.,
2000; Sawyer et al., 2001; Sawyer et al., 2005). For many patients, modulators
have improved their quality of life and reduced many of CF’s associated
symptoms. Additionally, sex education for adolescents varies around the world
(Lameiras-Fernándex et al., 2021). These differences may influence attitudes of
the studied population and necessitates a closer look at a US focused
population.
Our research aimed to understand the outlook on fertility, family planning,
birth control, and contributing factors for men with CF. It is reasonable to
hypothesize that improvements in quality of life and increase in life expectancy
due to modulator therapy may increase the desire to have children and therefore
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a negative reaction to probable infertility. Exploring this hypothesis was a main
goal of the current study. The current study also piloted a possible method for
providing men with CF personalized fertility information using the SpermCheck®
Fertility Home Test for Men (SCFT). The SCFT was approved for home use by
the Food and Drug Administration (FDA) in 2010 and can be used by men to
screen for potential fertility (Chan, 2010). The current study assessed a limited
number of participants’ perspective of the ease of use with this at-home test and
determined if the results may have affected their perspective of their own fertility.
2.3 Methods and Materials
2.3.1 Participants and Recruitment
Participants were invited to take part in an online survey (Appendix A) via
a flyer (Appendix B) distributed by Cystic Fibrosis Centers and social media
groups. Social media posts included a digital copy of the flyer circulated to the
following Facebook pages and groups: Cystic Fibrosis, Cystic Fibrosis
Foundation, Cystic Fibrosis Community, and Trikafta/Kaftrio Cystic Fibrosis.
Inclusion criteria, goals of the study, researcher contact information, and a QR
code for direct survey access were included on the flyer. In order to take part in
this study, participants had to be over the age of 18, assigned male at birth, have
a diagnosis of CF, and be fluent in English reading and writing. Taking the survey
was voluntary; participants could exit the survey at any time. Upon completion of
all survey questions, participants were presented with a link to an additional
questionnaire (Appendix C) where they could register to receive a $5 Amazon egift card, if they were one of the first 50 participants.
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At the end of the survey, participants had the opportunity to indicate if they
were interested in the second part of the study (part two) which included
receiving and completing the SCFT as well as a follow up phone interview to
discuss their results. If interest in part two was indicated, the primary investigator
called the participant using the provided phone number to explain the process
that would be involved in part two. A script was used to ensure all points were
covered (Appendix D). This included explaining the possible benefits and risks as
well as answering any questions. If the participant was still interested, they
provided an email address to which a consent form (Appendix E) was sent. All
consent processes, survey materials, and the study as a whole was approved by
the University of South Carolina Institutional Review Board (ID: Pro00117594).
2.3.2 Procedure
The online survey was created through Qualtrics.com and included
multiple choice, open-text, and Likert scale items. Survey items inquired about
participant demographics, CF history, number of current children, number of
children desired, outlook on fertility, and outlook on family planning. All questions
were voluntary, excluding questions required to determine if participants met
inclusion criteria. The survey was open from January 6, 2022, to February 4,
2022. A total of 300 responses to the survey were recorded. Only 277 of these
met the inclusion criteria for the study. However, a number of these responses
were found to be fraudulent; therefore, a method for eliminating the fraudulent
responses from the data set was designed (Figure 2.1). A combination of
recommendations from various sources was used to develop this data sieve
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(Qualtrics, 2021; Simone, 2019). Ultimately, 75 responses were included in data
analysis.
Total Recorded
Responses that
met inclusion
criteria (277)

Completed all
presented Lichert
Scale quetions
(211)

Completed survey
in 3 or more
minutes (169)

Responses from
unique IP
addresses (162)

Responses with a
Q_Recaptcha
score >0.5 (153)

Redundent
questions
answered
concordantly (116)

Unique responses
(76)

Responses from
valid email
addresses (75)

Did not complete
all presented
Likert Scale
questions (66)

Completed survey
in less than 3
minutes (42)

Responses from
duplicate IP
addresses (7)

Responses with a
Q_Recaptcha
score <0.5 (9)

Redundent
questions
answered
discrepantly (37)

Responses that
were identical to 2
or more other
responses (40)

Responses from
invalid email
addresses (1)

Figure 2.1 Methods by which survey responses were filtered to maintain data
integrity. Responses included in black boxes were excluded from the data
analysis.
Thirteen survey respondents indicated that they would like to learn more
about part two of the study. These respondents were contacted by the primary
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investigator using the information provided in the last questions on the survey.
This initial phone call followed a script (Appendix D) to ensure that all relevant
information was disclosed. At the conclusion of this phone call, participants were
asked to provide an email address if they were still interested in participating in
part two of the study. Nine participants provided an email address in order to
receive the written consent form (Appendix E). Four participants returned a
signed consent form via email. These four participants were called to schedule a
time for a phone interview and obtain needed information for shipping the SCFT.
This phone call followed a script to ensure relevant information was disclosed
(Appendix F).
After the phone interview was scheduled and the SCFT was sent, an
email (Appendix G) including SCFT instructions (Appendix H) was sent to the
participant. The SCFT is a rapid qualitative immunodiagnostic home test that
detects the presence of sperm in semen. An immunochromatic strip functions to
detect sperm at a 20,000,000 sperm/mL concentration. Meaning, the SCFT can
detect normal sperm count and lower than expected sperm count; not
distinguishing between oligospermia and azoospermia. SpermCheck® also
produces an at-home post-vasectomy sperm test that can detect the presence of
sperm at a concentration of 250,000 sperm/mL. All four participants were then
called at the scheduled time and semi-structured interviews were conducted
(Appendix I). These interviews were recorded via audio recording and then
transcribed by hand. Recordings were destroyed after transcription.
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2.3.3 Data Analysis
Quantitative survey data was analyzed using descriptive statistics and
assessed for correlations utilizing Microsoft Excel and IBM Statistical Package for
the Social Sciences (SPSS) version 28.0.0.0 (190). In order to improve data
analysis, the five-point Likert scale questions were combined into three-point
scales. Strongly agree and agree were combined into agreement; strongly
disagree and disagree were combined into disagreement. This increased group
sizes for agreement and disagreement while maintaining authentic data. A chisquare test of goodness-of-fit was performed via SPSS to determine if there was
a significant relationship between desire for a future child and whether
participants had taken modulator therapy. A similar test was also performed to
determine if there was a significant relationship between the participant feeling
they would enjoy parenting a child and whether they had taken modulator
therapy. An alpha level of .05 was used for all statistical tests.
Some open response questions were also combined into categories
including the number of current and desired children, as well as the educator who
explained the likelihood of infertility in men with CF. For questions that were not
answered that required numbers, zeros replaced missing data. For unanswered
questions that required descriptive responses, “no response” was recorded.
Interview responses were analyzed for themes, but due to small sample
size, these responses were ultimately summarized, and quotes were used to
support concepts evaluated in the survey. There were several close-ended, yes
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or no questions in the phone interview; these responses are reported in
frequencies.
2.4 Results
2.4.1 Demographics
The age of participants ranged from 18-60 years old; the average age of
participants was 31 years old. The majority of participants were 30 years old or
younger, white or Caucasian, and non-Hispanic (Table 2.1). The respondents
reported mostly being sexually attracted to women, exclusively (92%), while a
few were sexually attracted to only men (7%) or attracted to women, men, and
non-binary people (1%). Most participants were single (41%), 27% were in longterm relationships, and 32% were married.
Table 2.1 Participant Demographics
Participant demographics (N=75)
Age
18 to 30 years old
31 to 40 years old
41 to 50 years old
51 to 60 years old
Race
White or Caucasian
Black or African American
Other
Native Hawaiian or other Pacific
Islander
No response
Ethnicity
Non-Hispanic
Hispanic or Latino
No response
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Total (n)

Percentage (%)

45
19
6
5

60%
25%
8%
7%

55
16
2
1

73%
21%
3%
1%

1

1%

60
3
12

80%
4%
16%

2.4.2 Cystic Fibrosis History
Participants reported a variety of genotypes (Figure 2.2). As expected,
F508del (n=44) was the most commonly reported variant followed by R117H
(n=12), G542X (n=10), and G551D (n=7). Seven participants did not know their
genotype and 38 participants only reported one variant. Of the total 75
participants, 54 (72%) indicated that they were pancreatic insufficient and 39
participants (52%) indicated that they have taken or are currently taking
modulators.
Class 1
• G542X
• R553X
• 621+1G>T
• Q685X
• W1282X
• E585X
• 1717-1G
• 2184delA

Class 2
• F508del
• N1303K
• I507del

Class 3
• G551D

Class 4
• R117H
• D1152H

Class 5
• 2789+5G-A

Figure 2.2 Reported CFTR variants by class
Age ranges were used to elicit how old participants were at the time of
diagnosis. Almost half of participants (48%) were diagnosed at less than 1 year
of age, 23% of participants were diagnosed with CF between the ages of 1 and 9
years old, 12% were diagnosed between 10 and 19 years old, 15% were
diagnosed with CF at 20 years old or older, and 2% of participants did not report
their age at diagnosis.
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2.4.3 Fertility Data
Four of the 75 participants (5%) reported they did not recall any previous
education about the possible infertility for men with CF. Participants who
indicated they had learned about possible infertility for men with CF were asked
to recall their age when they learned about infertility and who took on the role of
educator (Table 2.2). Participant responses regarding who educated them about
the possibility of infertility were categorized into the following groups: medical
professionals, family, self-educated, or other. The two responses that fell into the
other category reported being told by “other CF patients and their parents” and “a
random classmate”.
Table 2.2 Recollection of Infertility Education Timing and Source
Education on Infertility (N=75)
Total (n)
At what age did you learn about possible infertility?
Less than 10 years old
4
Between 10 and 15 years old 22
Between 16 and 20 years old 30
21 years old and older
15
Never
4
Who taught you about possible infertility?
Medical Professional
35
Self-Educated
13
Family
7
Other
2
No response
14

Percentage (%)
5%
30%
40%
20%
5%
49%
18%
10%
3%
20%

The four respondents who did not recall any education about CF related
infertility from any source were spread among various ages of diagnosis;
however, all men who reported being diagnosed under the age of one year old
did recall being educated about infertility (Table 2.3).
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Table 2.3 Recollection of Infertility Education by Age at Diagnosis
Age at Diagnosis (N=75)

Recall
Education n (%)
36 (100%)
16 (94%)
7 (78%)
10 (91%)

Less than 1 Year Old
Between 1 and 9 Years Old
Between 10 and 19 Years old
20 Years Old or Older

Do Not Recall
Education n (%)
0 (0%)
1 (6%)
2 (22%)
1 (9%)

Most respondents recalled being educated about infertility between the
ages of 10 and 20 years old (Figure 2.3). Medical professionals were the most
reported source of information in all age groups, with the exception of males who
were under the age of 10 when they first learned of infertility in men with CF.

Source of Infertility Education (N=57)

Number of Particiapnts

30
25
20
15

5%

5%
18%

26%

9%
22%
7%

16%

10

68%
5
0

53%

71%

50%
50%
Less than 10

10 to 15

16 to 20

21 and older

Age at Education on Infertiilty (years)
Medical Professional

Family

Self

Other

Figure 2.3 The age at which participants were educated about possible infertility
and their source of education
A previous clinical sperm count was reported by 40 participants (53%).
Age at which semen analysis took place was not collected; however, current age
was considered. Only one participant currently under the age of 20 reported
having completed a clinical sperm count. Further, only 18 out of 45 participants
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who were 30 years old or younger had completed a clinical sperm count. Of the
40 participants who had completed a sperm count, five participants (13%)
indicated a typical number of sperm. Of these five men, two of them reported
having biological children. Two had at least one F508del variant, one reported his
genotype as R1177H and G542X, and the remaining two reported only one
variant- G542X and R117H, respectively.
Of the four men who completed the SCFT, all men had results that
indicated a sperm count less than 20,000,000 sperm/mL. All of these men
reported at least one F508del variant in CFTR.
2.4.4 Number of Children
Most participants (n=58, 77%) did not have any children at the time of the
survey. However, some participants (n=17, 23%) reported that they did have
children via various family building methods- biologically, via donor sperm,
adoption, or stepchildren (Table 2.4). Mode of conception for biological children
was not elicited. Although participants had the opportunity to report children
whom they were unsure if they were the biological child, no participants reported
any children of uncertain paternity.
Table 2.4 Current Number of Children
Number of Current Children (N=75)
Biological
Zero
One or more
Donor
Zero
One or more
Adopted
Zero
One or more
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Total (n)

Percentage (%)

65
10

87%
13%

74
1

99%
1%

72
3

96%
4%

Step
Zero
One or more

71
4

96%
6%

Using Likert scales, 58 participants (77%) agreed that they would enjoy
some or all aspects of being a parent and 49 participants (65%) indicated that
they would like to have at least one additional child in the future through various
means. Of the 20 participants who were in long-term relationships, 18 (90%)
desired a child in the future, the most likely among all relationship statuses
reported. Of participants who were married, 14 out of 24 desired a child in the
future (58%).
Single participants were the least likely, although not unlikely, to report
that they desire a child in the future with 17 out of the total 31 single participants
indicating they would like a child in the future (55%). Single men under the age of
30 reported wanting a child or not wanting a child in the future at equal rates.
Those in the age groups most likely to want a child in the future, 18 to 30 years
old and 31 to 40 years old, were also most likely to be in long-term relationships
or married.
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A

B

Participants Who Desire a
Future Child (N=49)

35

35

30

30

Number of Participants

Number of Participants

Participants Who Do Not
Desire a Future Child (N=26)

25
20
15
10
5
0

25
20
15
10
5
0

18 to 30 31 to 40 41 to 50 51 to 60

18 to 30 31 to 40 41 to 50 51 to 60

Current Age Group

Current Age Group

Single

Long-term

Married

Single

Long-term

Married

Figure 2.4 Relationship status of participants who do and do not desire a future
child.
Participants’ desire for a future child was also considered in the context of
whether they had taken modulator therapy (Figure 2.5). A chi-square test of
goodness-of-fit was performed to determine if desire for a future child was
equally distributed among the two groups. A significant relationship was found,
X2 (1, N=75) =4.82, p=.028. Out of our 75 participants, 39 indicated they were
taking or had taken modulators in the past. The remaining 36 had not taken
modulators. Those who had taken modulators were more likely to indicate that
they desire a child in the future. Participants who had taken modulators were also
significantly more likely to report that they felt they would enjoy parenting a child,
X2 (2, N=75) =6.07, p=.048.
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Desire for a Child in the Context of Modulator Therapy (N=75)

Modulators (-)

53% (n=19)

Modulators (+)

47% (n=17)

77% (n=30)

0%

10%

20%

30%

Desire a Child

40%

23% (n=9)

50%

60%

70%

80%

90%

100%

Do not desire a child

Figure 2.5 Desire for a child in the context of modulator therapy status
Out of 75 total participants, 60 (80%) agreed that they have wanted a
biological child at any point. Of those 60 participants, 41 indicated that they
currently desire a biological child in the future (68%). Additionally, 5% of
participants indicated that they would like to have a child via sperm donation,
11% indicated that they would like to adopt a child, and 5% indicated they would
like to become a father figure to stepchildren in the future.
2.4.5 Outlook on Fertility
Likert scale items regarding outlook on fertility were categorized into three
categories: perception, anxiety, and embarrassment (Table 2.5). Responses
were described by the source of fertility information (Figure 2.6), age at
education, and current age. No statistical difference was appreciated when
comparing perception questions by source of education, age at education, or
current age. Most participants felt they were likely infertile and agreed that their
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perception of their fertility had affected their family planning. All 75 participants
responded to each of these statements.
Table 2.5 Outlook on Fertility
Outlook on Fertility (N=75)
Perceptions
I feel that I am likely infertile
I feel that my perception of my fertility has
affected my family planning
I think infertility is a significant burden of Cystic
Fibrosis
Anxiety
I have felt worried that I would not be able to
father a biological child
I have felt worried about how my fertility may
affect my romantic relationships
Embarrassment
I have felt embarrassed about the possibility that
I may be infertile
I have avoided disclosing information about my
fertility to romantic partners in the past
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Agree
n (%)

Neutral Disagree
n (%)
n (%)

53
(71%)
39
(52%)
51
(68%)

13
(17%)
21
(30%)
17
(23%)

9
(12%)
15
(20%)
7
(9%)

43
(57%)
42
(56%)

22
(30%)
13
(17%)

10
(13%)
20
(27%)

35
(47%)
29
(39%)

15
(20%)
15
(20%)

25
(33%)
31
(41%)

"I have felt worried that I would not be able to
father a biological child"

A
100%
90%
80%
70%

29

100%

8
8

11
42

90%

50

70%

84

60

20%

30%

50

14

10%

14

0%
Medical
Professional

Family

Self

Other

Medical
Professional

"I have felt embarrassed about the possibility
that I may be infertile"

100%

Family

Self

50

Other

"I have avoided disclosing information about
my fertility to romantic partners in the past"

D
100%

15

26

90%

80%

80%

23

70%

23

71

60%

100

50%

40%
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40

70%

71

50%

20%

8

61

60

20%

0%

30%

50
72

40%

29

10%

60%

31

50%

29

40%

90%

20

60%

50%

C

20

80%

60%

30%

"I have felt worried about how my fertility may
affect my romantic relationships"

B

20

31

40%

62

51

30%
20%

29

10%

100

40

10%

0%

29

31

Family

Self

0%
Medical
Professional

Family

Self

Other

Medical
Professional

Other

Figure 2.6 Frequency of agreement (green), neutrality (blue), and disagreement
(yellow) with statements used to evaluate fertility outlook by information source:
Medical Professional (n=35), Family (n=7), Self (n=13), and Other (n=2)
2.4.6 Birth Control Practices
Using Likert scales, participants who responded that they were sexually
attracted to women (n=70) indicated if they agreed or disagreed with specific
statements regarding personal use of birth control (Table 2.6). Participants also
had the option to indicate that their feelings were neutral about any of the
presented statements. These statements were used to assess each individual's
outlook on birth control and condoms.
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Table 2.6 Outlook on Birth Control
Outlook on Birth Control (N=70)

Agree Neutral Disagree
n (%) n (%)
n (%)

Perceptions
My knowledge or perceptions of infertility have
changed my personal use of birth control
methods, including condoms, in the past
Responsibility
I do not feel obligated to use birth control or
condoms for the purpose of preventing
pregnancy because of my assumed fertility
status
I rely on my partner to take responsibility to
prevent pregnancy
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46
(66%)

12
(17%)

12
(17%)

39
(56%)

17
(24%)

14
(20%)

17
(24%)

18
(26%)

35
(50%)

A

“My perceptions of infertility have changed my personal use of birth
control”

16%

14%

70%

B

C

“I do not feel obligated to use
birth control for the purpose of
preventing pregnancy”

“I rely on my partner to take
responsibility to prevent
pregnancy”

12%

18%

24%
60%

64%

22%

Figure 2.7 Frequency of agreement (green), neutrality (blue), and disagreement
(yellow) for men who are attracted to women and feel they are likely infertile with
statements used to evaluate outlook on birth control (n=50)
Of respondents who felt that they were likely infertile, 70% agreed that this
altered their use of birth control in the past (Figure 2.7 A). Only 31% of
respondents indicated that their perception of their fertility changed both their
plans to have children and their plans to avoid having children and 4% indicated
that their understanding of their fertility changed neither their plans to have
children or prevent pregnancy.
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The level of how responsible respondents felt to prevent a pregnancy was
also evaluated. Nearly equal numbers of men who feel they are likely infertile do
not feel obligated to use birth control to prevent pregnancy (Figure 2.7 B) and do
not rely on their partner to prevent pregnancy (Figure 2.7 C).
When asked about condom use, 69% of respondents reported having
used a condom in the past for any reason. Men who were educated about
infertility by family members were the most likely to report that they have used
condoms in the past for any reason (86%). Those who learned about infertility
independently reported the lowest use of condoms (50%).
2.4.7 Phone Interviews
Of the four participants who completed the SCFT, all of them completed
the test, had results that indicated a below typical sperm count, felt that the
instructions that came with the test were easy to follow, understood how to read
the results of the test, believed the results of the test were accurate, and felt that
access to this type of test would be helpful to other men in the CF community.
None of the respondents felt that the results of the test would change their
current birth control practices or family plans. Quotes from the respondents were
organized by themes (Table 2.7). One of the themes, relief from confirming
assumed infertility was cited by interviewees as the biggest reason they felt
access to this test would help others.
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Table 2.7 Themes Identified in Phone Interviews
Themes Identified in Phone Interviews (N=4)
Initial sadness
“I kind of expected the results that I got, but at the same time it was…
…eye opening? … I don’t know. It made me feel sad for a few seconds.
Like the realization of it, but… …I expected it.”
Sense of relief from confirmation of assumed infertility
“I think it’s just a way of probably confirm[ing] things. Because, you
know, within clinic and stuff they talk about it but there’s no real way of
testing or anything. They don’t give you any options as far as how to test
certain things.”
“It’s nice to officially know. *laughs* So I guess there’s less of the doubt
in my head. Like ‘well, you know, I technically don’t know’ so now I
believe it. I was kind of expecting it. I was 99.9% sure this would be the
case. So, it’s nice to have that confirmation.”
“Like 90 plus, probably even north of 90 plus, you know, do not have the
vas deferens. So that’s always just what is taken for gospel but, you
know, I’m happy that we are kind of able to confirm it in our own right
versus just being told something and believing it.”
“I guess it’d give you an idea and kind of answer, maybe sum up or
answer some questions you might have about yourself fertility wise.”
“I had a pretty good idea I wasn’t fertile, but it’s good to have information
on stuff. Be able to pass information along.”
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Lack of resources or options for fertility information and testing
“I wish I knew more about how available it was. For what it’s worth I
thought I always had to go to like a LabCorp or like a professional
diagnostic agency to get this done, not at home.”
“Had I known this was so affordable and I could do it from the comfort of
my own home I honestly probably would have done it back in my early
20s.”
“[Infertility is] something that the patient is going to deal with forever.
They should at least know everything can know about it.”
“I mean you get information on everything else. They have booklets and
packets for everything else, but they don’t have hardly anything on that.”

2.5 Discussion
2.5.1 Infertility Education
Most men in this study were diagnosed with CF early in life and recalled
learning about possible CF related infertility at some point. However, some
participants reported being diagnosed with CF later in life after being diagnosed
with infertility. Few participants reported that they had not been previously
educated about the possible infertility for men with CF, which aligns with studies
by Sawyer et al. in 2005 and Fair et al. in 2000 who each found similar rates of
men who did not recall infertility education. However, it is possible that many of
these men or their primary caretakers may have been educated about infertility,
but men did not remember that conversation at the time of the survey. Record
review was not possible in the current study to assess if men truly did receive
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infertility education. A publication, which surveyed medical professionals who
care for men with CF in Massachusetts, found that all participants reported they
speak to adolescent patients about probable infertility (Sawyer et al., 2001). If
that is consistent across all healthcare providers, there may have been some
form of infertility education that was not recalled by our participants.
Sawyer et al. (2005) found that males were most likely to be educated
about possible infertility between the age of 16 and 20 years, with the average
age at education being 16 years old. The majority of our participants also
recalled being educated in the same age range. On average, Sawyer et al.
(2005) found their participants preferred age of education was 14 years old. In an
earlier study, Sawyer et al. (2001) published that healthcare professionals feel it
is most appropriate to discuss infertility at 13 years of age, although most report
delaying this discussion until 15 years of age. Less than one third of our
respondents reported learning about infertility in the age range that
encompassed these previously established ages. Most participants in our study
recall learning this information from a healthcare professional. However, no
respondents were educated by a healthcare professional before the age of 10
years old, but there were instances of participants learning this information
independently before the age of 10. Together, these findings indicate that men in
our sample recall being educated later than they may have desired and later than
healthcare professionals feel is appropriate. This illustrates the need for
standardized guidelines for educating male patients with CF about infertility at an
age that is thought to be beneficial by both patients and physicians.
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Our finding that all individuals who were diagnosed before one year of age
recall their education about possible infertility may be expected if the individuals
are being followed regularly throughout childhood and early adolescence by
healthcare professionals who specialize in CF and are aware of the importance
of educating young men about possible infertility. In formulating
recommendations about how and when to inform males with CF about possible
infertility it will be important to consider the age at which individuals are
diagnosed. If a patient is diagnosed after the recommended age for disclosing
fertility information, it is important to ensure that the individual still receives
appropriate fertility counseling. Regardless of age at diagnosis, our findings
indicate that it is important to repeat and present this information more than one
time; this would likely increase rates of recall.
2.5.2 Fertility Testing
About half of our participants reported that they had a clinical sperm count
completed. Although this is a high percentage of men, when considering the
population that is likely to have interest in participating in this research project,
this is not surprising. Sawyer et al. (2005) found a similar rate of semen analysis
for men with CF in their study. Among total participants in our study, 41 (55%)
indicated that they currently desire a biological child in the future. Nearly half of
these men had previously completed a clinical sperm count and reported a result
of low or no sperm, confirming their infertility. These men would need to use
Assisted Reproductive Technology (ART) to conceive a biological child.
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One eighth of men in our study who have completed a semen analysis
reported a typical sperm count, which is higher than the historically reported
fertility rate of 2-3% (de Souza et al., 2018). Although unexpected, there are
several explanations for this. The first possible explanation is that historically
published fertility rates may underestimate the true prevalence of fertility in men
with CF, especially in the context of nonclassical CF. There is also the possibility
that these may have been fraudulent responses that were not filtered. A third
explanation is that some of these men misunderstood or misreported the results
of their clinical sperm count.
Although age and relationship status clearly influence the desire to have a
child in the future, being single also does not eliminate the desire to have a child
in the future. The desire for children can change overtime. Sawyer et al. (2005)
found that most men with CF desired fertility testing prior to the age of 20, which
is generally thought to be earlier than the age of partnering for most people. The
age at which semen analysis took place was not evaluated by our survey;
however, the current age of our participants who have not had semen analysis
may indicate that men should be offered this testing earlier. The feeling that
semen analysis should be offered sooner was also expressed by participants in
the phone interviews. One participant clearly stated he would have completed
some kind of fertility testing “in [his] early 20s” if it were available.
The means by which men obtained a sperm count was not evaluated. It is
possible that healthcare providers could include information on the SCFT when
discussing options for accessing fertility. Although the SCFT can be an affordable
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or timely alternative, it should not replace clinical testing. In some instances,
SCFT may be an appreciated resource for patients. Future studies may consider
examining if fertility testing is routinely offered or if it generally happens at the
request of the patient. It is possible that fertility testing is delayed for men with CF
due to the average age that fertility testing is thought to be appropriate for the
general population. Most individuals undergo fertility testing after failed attempts
to conceive naturally, typically for one year; this protocol is clearly not appropriate
for men with CF.
2.5.3 Desire for Children
Overall, the majority of men in our study expressed a desire for children in
the future. Men who had taken modulators were much more likely to report that
they desire a child in the future despite the fact that modulators are not expected
to alter the infertility of men with CF, which is typically caused by irreversible
CBAVD. Studies that were done prior to modulator therapy found that lung
function was not directly related to the importance of having a child and selfreported health status was also unrelated to wanting a child (Fair et al., 2000;
Sawyer et al., 2005). While the men in our study who had taken modulators
reported wanting a child in the future at similar rates to men in previous studies,
men in our study who had not taken modulators reported much lower rates of
wanting a child. Our study did not specifically elicit reasons that participants do or
do not desire a child, which may be a topic for future research. It is possible that,
as more modulator treatments become available improving the quality of life and
extending life expectancy for patients, more men with CF will want to explore the
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possibility of fatherhood. This could be because of a reduction in perceived risk
of morbidity and mortality for men with CF whose symptoms are improved while
taking modulators.
Interestingly, more participants agreed with the statement “I want/wanted
biological children” than those who indicated they want a child in the future. This
indicates that the desire for children can change over time making it important to
offer a balanced education to all men with CF regardless of current plans for
children.
Three participants (5%) indicated that they would like to have a child via
sperm donation; one of these men had not yet had a clinical sperm count. These
same three participants indicated that they would also consider adopting a child
in the future. A total of six men (8%) indicated that they would like to adopt a
child in the future, with half exclusively considering adoption in order to parent a
child. It is possible that men may want to exclusively adopt for many reasons.
The sample size limits further analysis on this concept, but this may indicate that
there are additional variables contributing to family planning preferences that
were not measured. These may include feeling drawn to the concept of adoption
independent of any CF related factors or may be related to other health problems
caused by CF. Together, these findings indicate that family planning is fluid and
changes over time. Fertility education should include discussion about family
building options as well as clinical fertility testing.
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2.5.4 Outlook on Fertility
Although source of education did not have a significant role in perception
of infertility, the ethos of the information source has not previously been
considered for effectiveness of fertility counseling in males with CF, to our
knowledge. In contrast to perception of infertility, anxiety levels varied based
upon the recalled source of education for men with CF on infertility. Men who
reported learning of possible infertility independently indicated that they felt the
most worry or anxiety about being potentially unable to father a biological child
when compared to all other respondents. Strikingly, men who recalled being
educated by a family member, typically their mother, reported the least anxiety
about infertility. Anxiety levels did not seem to differ significantly based on current
age groups or the age at which men were educated on infertility. This may
indicate the need for collaborative counseling by both healthcare professionals
and family members.
Embarrassment was also measured to evaluate the outlook of
respondents and compared based on the person who educated the men about
infertility. Nearly half of respondents reported having felt embarrassed about the
possibility of infertility and some reported avoiding disclosing fertility information
to romantic partners. Similar to feelings of anxiety, participants who learned of
infertility independently reported higher frequencies of feeling embarrassed about
the possibility of being infertile. Sawyer et al. (2001) found that many healthcare
providers delay education about possible infertility due to potential
embarrassment. Our findings do show that some patients feel embarrassed
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about possible infertility; however, this does not depend on source of infertility
education. Future studies may consider specific methods for or approaches to
fertility counseling for adolescents that may reduce embarrassment.
2.5.5 Birth Control Practices
The level of how responsible respondents felt to prevent a pregnancy was
also evaluated. Most participants who feel no obligation to use birth control
indicated that they also do not rely on their partner to prevent pregnancy.
Additionally, the majority of men who had not yet had a clinical sperm count
indicated that they do not feel obligated to use birth control to prevent pregnancy.
These men may be using assumed infertility as a means of preventing an
unplanned pregnancy.
In order to better understand birth control practices of men with CF, we
compared their perceptions of infertility with their feelings of responsibility to use
birth control and their use of condoms. Nearly three-quarters of heterosexual
participants who reported feeling infertile agreed that their understanding of CF
associated infertility affected their use of birth control. The questionnaire did not
ask participants to specify how infertility changed their birth control practices.
However, the majority of those who indicated they do not feel obligated to use
birth control to prevent pregnancy indicated that they also do not rely on their
partner to prevent pregnancy.
When asked about condom use, 69% of participants reported using
condoms in the past, for either pregnancy prevention, sexually transmitted
infection (STI) protection, or both. The results of our study appear to be
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consistent with Sawyer et al. (2005) who found that a third of their participants
felt they did not need to use a condom due to their likelihood of being infertile.
Additionally, there are many other reasons men may decide to not use a condom
during sexual intercourse. Future studies could consider exploring specific birth
control methods used among men with CF. Condoms are the only form of birth
control that also decreases the risk of being infected with a STI. Although it is
important that men with CF do not rely on unconfirmed fertility status as birth
control, fertility counseling could also be an important opportunity for healthcare
providers to educate their patients about the use of condoms to prevent STIs.
Perceptions of family planning and perceptions on birth control are related
but distinct concepts. An individual’s perception of family planning can be thought
of as the steps they would take to grow their family, while an individual’s
perception of birth control can be thought of as the steps they would take to avoid
growing their family. Less than one third of respondents indicated that their
perception of their fertility changed both their plans to have children and their
plans to avoid having children while only a few indicated that their understanding
of their fertility changed neither their plans to have children or prevent pregnancy.
This may be affected by their desires to have or not have children. However, two
thirds of participants indicated that their understanding of their fertility only
affected their perception of family planning or only affected their use of birth
control. This may reflect imbalances in their education. Family planning and birth
control should both be discussed equally during educational counseling on
fertility.
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2.5.6 Strengths and Limitations
This study explored a novel concept in the target population of men with
CF receiving care in the US. Even globally, few studies have been done that
specifically look at the attitudes of men with CF surrounding fertility and birth
control. When considering the recent advances in care for men with CF, this
study is essentially the first of its kind in the new era of CFTR modulators.
Additionally, this study looked at many other factors that may influence how men
feel about fertility.
Sexual orientation information collected on respondents was used to
evaluate their use of birth control and condoms for the purpose of pregnancy
prevention. It may have been better to ask about past sexual encounters
specifically. Men who indicated they were exclusively attracted to other men were
not presented with the questions used to evaluate birth control practices;
however, it may not be appropriate to assume that they have never had a sexual
encounter with a female. Additionally, men who reported they were attracted to
women were asked these questions without determining if they had ever been
sexually active. More than half of our respondents indicated they were in a longterm relationship or married; asking about their current and historic birth control
practices separately may have been more informative due to possible
discontinued condom use in a committed relationship (Reece et al., 2010).
This study was limited by a small, convenient sample obtained from
Facebook and, unfortunately, some data integrity may have been lost due to
fraudulent responses. We were unable to perform a comprehensive qualitative
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analysis, limited by number of participants. This is, however, an important goal
for future work. Lastly, the goal of this project was to describe and better
understand the factors effecting the outlook on fertility and birth control use in
men with CF; in the future, it may be important, in larger samples, to use
advanced statistical techniques to better understand nuances of the experiences
of men with CF around fertility.
Further, it is unclear if our participant population reflects that of the
broader population of men with CF. Several differences in our data and the data
published by the Cystic Fibrosis Patient registry were noted (CFF, 2021). For
example, the demographic information collected from the survey participants was
unexpected and not consistent with population rates of CF across racial and
ethnic groups. Approximately one fifth of participants reported their race to be
black or African American. In comparison to the Cystic Fibrosis Foundation
Patient registry published in 2021 which reported 4.7% of patients with CF were
African American, this is a much larger portion of our sample than we would
expect (CFF, 2021). There is a possibility that this could be the result of a small
sample size or reflect the cultural identity of respondents rather than their
ancestry. The demographics of each Facebook group used to distribute the
survey are not known but may explain this finding as well. Our study was also
limited by self-reported genotype data. The four most common variants reported
by our survey respondents were in alignment with the four most common variants
in the Cystic Fibrosis Patient registry (CFF, 2021). However, while only 59% of
survey respondents indicated they had at least one F508del, the Cystic Fibrosis
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Patient registry reports that 85.8% of those affected by CF carry at least one
F508del variant. This may be a result of the small sample size, participants only
reporting one variant, or not knowing their genotypes at all. Another discrepancy
from the Cystic Fibrosis Patient registry was observed when assessing data
about pancreatic insufficiency. Although pancreatic insufficiency was reported by
nearly three quarters of participants in the current study, the Cystic Fibrosis
Patient registry published that 83.8% of patients utilized pancreatic enzyme
replacement therapy (CFF, 2021). Similarly, the patient registry reported that the
majority of individuals over the age of 12 years old (82.3%) were prescribed a
modulator therapy (CFF, 2021). Approximately half of our respondents indicated
that they had ever taken modulator therapy. There are obstacles and barriers to
receiving modulator therapy, such as insurance coverage, not having an eligible
genotype, financial hardship, side effects, or not being seen by a CF specialist
regularly who may be familiar with CF treatments. However, this is much lower
than would be expected in a truly representative sample of men with CF.
2.5.7 Future Directions
This study provides important background for future studies exploring
male fertility in CF. Replicating this study with refined survey questions and
confirming genotypes with a larger sample size could provide a clearer picture of
our current findings. Additionally, a study that takes place over a longer period of
time, developed to understand how outlook on family planning changes over a
lifetime for men with CF may also yield important information for making changes
in how men with CF are counseled on fertility. Focus groups consisting of
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healthcare providers, parents, and adult males with CF may be useful to
determine the most beneficial ways for parents and healthcare providers to work
collaboratively for the benefit of adolescent males with CF.
A larger study utilizing an at-home fertility test may also provide updated
information for men with CF and their providers. In the future, the use of
SpermCheck® Vasectomy Home Test for Men may be a more useful tool for
researchers than the SCFT utilized in the current study. The SpermCheck®
Vasectomy Home Test for Men detects a sperm concentration of 250,000
sperm/mL and above, which may be more useful for detecting CBAVD. Future
studies may also consider comparing experiences with at-home tests to
experiences of clinical fertility testing.
2.6 Conclusion
Most men in our study accepted and understood the likelihood that they
may be infertile regardless of their recalled source of education about infertility. A
large majority of participants reported learning about CF associated infertility
between the ages of 10 and 20 years old, usually from a healthcare provider.
There may be an impact on anxiety and embarrassment about infertility based on
when men learn about possible infertility and their source of that information.
Men who learned about infertility without professional or other outside guidance
were found to be more anxious and embarrassed than men who learned about
possible infertility from family or healthcare providers.
The majority of participants in this study indicated having a desire for a
future child at some point over their lifetime and some participants reported that
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they have already become a parent. More men who had taken modulators
expressed a desire for a child in the future than those who had not taken
modulators, despite the fact that modulator use does not reverse CBAVD, the
most common cause for infertility in men with CF. This difference in desire may
be related to their outlook if they experience increased quality of life and
improvement of symptoms while taking modulators.
When considering mode of conception, some men in our study were open
to alternative family building methods such as donor sperm or adoption. Younger
men and men who were single reported desire for future children at lower rates
than their older, partnered counterparts. This suggests that desire for children is
dynamic, changing situationally and over time.
Previous clinical fertility testing was also reported by more than half of
participants. While most reported below average sperm count, as is expected,
some reported normal sperm count. This underscores the need to offer fertility
testing or ultrasound to confirm the absence of the bas deferens as intact fertility
may be underestimated in men with CF.
Fertility testing is important for men with CF not only when considering
building their family, but also when considering options for family planning,
especially because some men in our study reported intact fertility. Those who
believe they are infertile are less likely to see a need for birth control. Although
many participants reported using condoms in the past, some did not. Condoms
are the only form of birth control that prevents the transmission of STIs and
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fertility education and counseling for young men with CF may be an important
education opportunity to discuss the importance of condom use.
When using the at-home fertility test as part of the current study, men
reported a favorable experience and all of them felt that an at-home testing
method should be offered to other men with CF. Reactions included initial
sadness for some, but all reported feeling relief that their suspected infertility was
now confirmed. Less uncertainty about their fertility status offered some of the
participants closure as well as information to discuss with their partners.
Participants also reported frustration regarding the lack of resources about CF
associated infertility and fertility testing options.
As for all individuals, there are many factors that affect the desire to have
or not have children for men with CF. Beyond personal preference, we identified
the counseling these men receive as an important factor that alters their thoughts
and feelings about family planning and birth control. More research needs to be
done to determine when, how, and by whom males with CF should receive
fertility information.
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CHAPTER 3
CONCLUSION
Most men in our study accepted and understood the likelihood that they
may be infertile regardless of their recalled source of education about infertility. A
large majority of participants reported learning about CF associated infertility
between the ages of 10 and 20 years old, usually from a healthcare provider.
There may be an impact on anxiety and embarrassment about infertility based on
when men learn about possible infertility and their source of that information.
Men who learned about infertility without professional or other outside guidance
were found to be more anxious and embarrassed than men who learned about
possible infertility from family or healthcare providers.
The majority of participants in this study indicated having a desire for a
future child at some point over their lifetime and some participants reported that
they have already become a parent. More men who had taken modulators
expressed a desire for a child in the future than those who had not taken
modulators, despite the fact that modulator use does not reverse CBAVD, the
most common cause for infertility in men with CF. This difference in desire may
be related to their outlook if they experience increased quality of life and
improvement of symptoms while taking modulators.
When considering mode of conception, some men in our study were open
to alternative family building methods such as donor sperm or adoption. Younger
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men and men who were single reported desire for future children at lower
rates than their older, partnered counterparts. This suggests that desire for
children is dynamic, changing situationally and over time.
Previous clinical fertility testing was also reported by more than half of
participants. While most reported below average sperm count, as is expected,
some reported normal sperm count. This underscores the need to offer fertility
testing as it may be underestimated in men with CF.
Fertility testing is important for men with CF not only when considering
building their family, but also when considering options for family planning;
especially because some men in our study reported intact fertility. Those who
believe they are infertile are less likely to see a need for birth control. Although
many participants reported using condoms in the past, some did not. Condoms
are the only form of birth control that prevents the transmission of STIs and
fertility education and counseling for young men with CF may be an important
education opportunity to discuss the importance of condom use.
When using the at-home fertility test as part of the current study, men
reported a favorable experience and all of them felt that an at-home testing
method should be offered to other men with CF. Reactions included initial
sadness for some, but all reported feeling relief that their suspected infertility was
now confirmed. Less uncertainty about their fertility status offered some of the
participants closure as well as information to discuss with their partners.
Participants also reported frustration regarding the lack of resources about CF
associated infertility and fertility testing options.
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As for all individuals, there are many factors that affect the desire to have
or not have children for men with CF. Beyond personal preference, we identified
the counseling these men receive as an important factor that alters their thoughts
and feelings about family planning and birth control. More research needs to be
done to determine when, how, and by whom males with CF should receive
fertility information.
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APPENDIX A
SURVEY
Cystic Fibrosis Fertility Status and Outlook
Thank you for your interest in participating in this research study! In this
study, researchers with The University of South Carolina, and collaborators a
The Medical University of South Carolina, hope to gather information about how
counseling on fertility has affected men with Cystic Fibrosis regarding family
planning and birth control practices.
This survey will take approximately 20 minutes. In order to be eligible for
this study, you must be 18 years old or older, assigned male at birth, and have
Cystic Fibrosis. This survey is completely voluntary and can be stopped at any
time without consequence. Your responses are anonymous and no identifying
information will be shared or published. By continuing, you are consenting to
participating in this part of this research study.
If you have any questions, please contact:
Allison Szczepanski
(XXX) XXX-XXXX
allison.perez@uscmed.sc.edu
Captcha Check Point
Demographics
1. What is your age? _____
2. Select your race (select all that apply)
White or Caucasian
Asian
Black or African American
American Indian or Alaska Native
Native Hawaiian or other Pacitic Islander
Other
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3. Select your ethnicity
Hispanic or Latino
Not Hispanic or Latino
4. Sex assigned at birth
Male
Female
5. My gender identity is…
Man
Woman
Non/binary/third gender
Prefer not to say
6. I am sexually attracted to… (select all that apply)
Men
Women
Non-binary/ third gender
7. My relationship status is…
Single
In a long-term, committed relationship
Married
Other
CF History
8. At what age were you diagnosed with Cystic Fibrosis?
Less than 1 year old
Between 1 and 9 years old
Between 10 and 19 years old
20 years old or older
9. What CFTR variants (mutations) cause your Cystic Fibrosis (please
select up to two)
F508del
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R117H
G542X
G551D
N1303K
621+1G>T
R553X
Something not listed here
I have the same mutation twice (homozygous)
I don’t know my mutation(s)
Display this question if “Something not listed here” is
selected:
What CFTR variants (mutations) cause your Cystic Fibrosis?
10. Are you pancreatic insufficient? (Do you take pancreatic enzymes?)
No
Yes
11. Have you ever taken a modulator? (Symdeko, alydeco, Orkambi,
Trikafta, or others)
Yes
No
Display this question if “yes” is selected:
Please explain your history with modulators briefly. What are
you taking, for how long, and what have you taken
previously?
________________________________________________
________________________________________________
________________________________________________
12. Have you learned about possible infertility for men with Cystic
Fibrosis?
Yes
No
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Display this question if “yes” is selected:
At what age did you learn about possible infertility?
Less than 10 years old
Between 10 and 15 years old
Between 16 and 20 years old
21 years old or older
Display this question if “yes” is selected:
Who taught you about possible infertility?
________________________________________________
________________________________________________
13. Have you ever completed a sperm count in a fertility clinic?
Yes
No
I am not sure
Display this question if “yes” is selected:
What were the results of your sperm count?
Normal range
Low sperm count
No sperm
Number of Children: Current and Future
14. How many children do you have? (fill in number values)
Biological ___
Donor conceived ___
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Adopted ___
Step ___
Unknown (I am unsure if I am the father) ___
Total number of children ___
15. In the future, how many children would you like to have? (fill in number
values)
Biological ___
Donor conceived ___
Adopted ___
Step ___
Total number of children ___
Fertility
Please indicate how much you agree with the following statements
16. I do/would enjoy some or all aspects of being a parent.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
17. I want/wanted biological children.
Strongly Agree
Agree
Neutral
Disagree
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Strongly Disagree
18. I feel that I am likely infertile.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
19. I feel that my perception of my fertility has affected my family planning.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
20. I have felt worried that I would not be able to father a biological child.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
21. I have felt worried about how my fertility may affect my romantic
relationships.
Strongly Agree
Agree
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Neutral
Disagree
Strongly Disagree
22. I have avoided disclosing information about my fertility to romantic
partners in the past.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
23. I have felt embarrassed about the possibility that I may be infertile.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
24. I think infertility is a significant burden of Cystic Fibrosis.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
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Family Planning
Display this question if “Women” is selected for question 6
25. My knowledge or perceptions of infertility have changed my personal
use of birth control methods, including condoms, in the past.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
26. I do not feel obligated to use birth control or condoms for the purpose
of preventing pregnancy because of my assumed fertility status.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
27. I have used condoms in the past, but only for prevention of STIs.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
28. I have used condoms in the past, to prevent STIs and pregnancy.
Strongly Agree
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Agree
Neutral
Disagree
Strongly Disagree
29. I rely on my partner to take responsibility to prevent pregnancy.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
30. I have felt worried my partner may become pregnant unexpectedly in
the past.
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
31. I think that probable infertility is a "silver-lining" of having Cystic
Fibrosis.
Strongly Agree
Agree
Neutral
Disagree
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Strongly Disagree
Interest in Part Two of Study
32. For the second part of this study, 10 participants can receive a free athome SpermCheck® Fertility Test kit and share their experience with
the test over the phone. Are you interest in learning more about
participating in the second part of the study?
Yes
No
Display this question if “yes” is selected:
Please enter your phone number if you would like to learn
more about the next part of this study. By entering your
phone number you are agreeing to be contacted by the
primary investigator of this study.
________________________________________________
Display this question if “yes” is selected:
Please enter your name. By entering you name you are
agreeing to be contacted by the primary investigator of this
study.
________________________________________________
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APPENDIX B
RECRUITMENT FLYER

Figure B.1 Recruitment Flyer
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APPENDIX C
OPTIONAL GIFT CARD QUESTIONNAIRE
Gift Card Information
Captcha Checkpoint
The information you enter here is sperate from your answers on the previous
survey. The information you enter in this survey will be used to contact you.
1. Would you like to receive a $5 Amazon girl card for your time? (subject to
availability)
Yes
No
Display this question if “yes” is selected:
Please enter your email address to receive a $5 Amazon egift card (subject to availability)
________________________________________________
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APPENDIX D
INITIAL PHONE CALL SCRIPT
Hello, my name is Allison Szczepanski. Am I speaking with [NAME PROVIDED
BY PARTICIPANT]?
Yes: *continue on*
No: Do you know when he may be available for a phone call? *Plan to call
back at that time*
I am calling to follow up about the survey you took for men with Cystic Fibrosis. I
am a genetic counseling graduate student at The University of South Carolina’s
school of medicine. I am in South Carolina undertaking research that will be used
in my thesis. This phone call is being recorded. Do you agree to this being
recorded?
Yes: *continue on*
No: Thank you for your time.
I am studying fertility outlook and status of men with CF. Thank you for the
information you provided in the online survey on [DATE OF SURVEY TAKEN].
You indicated that you may be interested in the second part of my study, so I
wanted to reach out and give you more information for the consenting process.
Are you still interested?
Yes: *continue on*
No: Thank you for your time.
There are a couple of points I will need to cover with you.
The next step in this research is exploring the rates of fertility in men with CF.
This will include participants taking an at home SpermCheck® test which will be
sent to their homes free of charge. Instructions will be included with the test kit
for review, but this would involve the participant providing a semen/ejaculate
sample and then placing it on the SpermCheck® device. After seven minutes, the
test would then indicate the presence or absence of sperm in the semen. In order
for the test to be accurate, the user must have ejaculated within the last week,
but not within the last two days prior to testing. In other words, the user cannot
have ejaculated within the last two days but must have ejaculated within the last
7 days. Ejaculation must occur between 7 and 3 days prior to testing to ensure
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accuracy of testing. This is only one measure of fertility and therefore it cannot be
considered a full fertility work up. Additionally, fertility status can change over a
person’s lifetime for many reasons.
If you decide to take part in this project, a time would be scheduled to speak on
the phone again within the two days after the test is completed. During that
phone call, you would be asked several questions about your experience using
the test and about the results. This phone call would take approximately 15
minutes.
The information provided during this conversation would be used to evaluate the
ways that men are currently counseled on fertility, how counseling methods could
be improved, how accurate the current estimates of fertility in men with CF are,
and determine if the SpermCheck® test may be useful for other men with CF.
All efforts will be made to keep the provided information and the results of the
test in the strictest confidentiality, but there is always a small chance of a breach
of confidentiality. Your name will not be linked to any of the data provided for the
study or any publication. The de-identified information may be used for
publication or shared with other researchers without additional consent from the
participants.
There is a chance that taking this test and hearing these questions during the
phone interview may make you feel unexpected emotions. Additionally, learning
that there is or is not sperm present in the ejaculate may make a participant feel
unexpected emotions.
Participation is voluntary. There will be no penalty or loss of benefits to which the
individual is otherwise entitled if the decision to not participate is made. You can
decline to answer any question; as well as to stop participating at any time,
without any penalty. This study has been approved by the University of South
Carolina internal review board.
The interview during the second part of the research, would be recorded in order
to ensure an accurate record of the information provided. The recording will be
transcribed by hand and the transcripts will be kept confidential and secured. The
recording will be erased after it is transcribed.
Do you have any questions about this research?
If you have any questions concerning this research in the future, please feel free
to contact me at any time. My contact information can be found on the post for
the original survey, the informed consent form, or I can repeat it now:
Allison Szczepanski
(XXX) XXX-XXXX
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allison.perez@uscmed.sc.edu
Would you like to participate in the second part of this study?
Yes: please provide your email address so that I may email you the official
informed consent form. *Participant gives email address*
Once I receive your signed consent form via email, I will call back to get
your mailing address and at that time we can schedule a time for the
phone interview about your results.
No: Thank you for your time.
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APPENDIX E
CONSENT FORM
UNIVERSITY OF SOUTH CAROLINA
CONSENT TO BE A RESEARCH SUBJECT
Fertility Status and Outlook of Males with Cystic Fibrosis
KEY INFORMATION ABOUT THIS RESEARCH STUDY:
You are invited to volunteer for a research study conducted by Allison Perez
Szczepanski. I am a graduate student in the School of Medicine Genetic
Counseling Program, at the University of South Carolina. The University of
South Carolina Genetic Counseling Program and The Medical University of
South Carolina Cystic Fibrosis Center are sponsoring this research study.
The purpose of this study is to evaluate perceptions of fertility and sexual
health practices in males with Cystic Fibrosis, evaluate patient experience
using a SpermCheck® home fertility test, and compare fertility outlook before
and after receiving results from the SpermCheck® home fertility test.
Typically, males with CF are quoted historic fertility data that suggest only 2 to
3% of men with CF are fertile. This data has been collected over decades of
research, but very few studies have focused specifically on fertility as it
relates to genotype. These studies documented that the infertility seen in
males with CF is caused by congenital bilateral absence of the vas deferens
(CBAVD). Although there are many other factors related to male fertility,
presence of sperm in ejaculate is an indicator that the vas deferens are not
absent and fertility may not be disrupted. You are being asked to participate
in this study because you participated in the first part of this study and
indicated that you would be interested in participating in part two. This study
is being done at The University of South Carolina and will involve
approximately ten volunteers.

The following is a short summary of this study to help you decide whether to
be a part of this study. More detailed information is listed later in this form.

The next step in this research is exploring the rates of fertility in men with CF.
This will include participants taking an at home SpermCheck® test which will
be sent to their homes free of charge. Instructions will be included with the
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test kit for review, but this would involve the participant providing a
semen/ejaculate sample and then placing it on the SpermCheck® device.
After seven minutes, the test would then indicate the presence or absence of
sperm in the semen. In order for the test to be accurate, the user must have
ejaculated within the last week, but not within the last two day prior to testing.
In other words, the user cannot have ejaculated within the last two days but
must have ejaculated within the last 7 days. Ejaculation must occur between
7 and 3 days prior to testing to ensure accuracy of testing. This is only one
measure of fertility and therefore it cannot be considered a full fertility work
up. Additionally, fertility status can change over a person’s lifetime for many
reasons.

If you decide to take part in this project, a time would be scheduled to speak
on the phone again within the two days after the test is completed. During that
phone call, you would be asked several questions about your experience
using the test and about your results. This phone call would take
approximately 15 minutes.

The information provided during this conversation would be used to evaluate
the ways that men are currently counseled on fertility, how counseling
methods could be improved, and determine if the SpermCheck® test may be
useful for other men with CF.

All efforts will be made to keep the provided information and the results of the
test in the strictest confidentiality, but there is always a small chance of a
breach of confidentiality. Your name will not be linked to any of the data
provided for the study or any publication. The de-identified information may
be used for publication or shared with other researchers without additional
consent from the participants.

There is a chance that taking this test and hearing these questions during the
phone interview may make you feel unexpected emotions. Additionally,
learning that there is or is not sperm present in the ejaculate may make a
participant feel unexpected emotions.

Participation is voluntary. There will be no penalty or loss of benefits to which
the individual is otherwise entitled if the decision to not participate is made.
You can decline to answer any question; as well as to stop participating at
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any time, without any penalty. This study has been approved by the
University of South Carolina internal review board.
PROCEDURES:
If you agree to participate in this study, you will do the following:
1. Return this signed consent form to the primary investigator by
emailing it to allison.perez@uscmed.sc.edu (a picture of the signed
consent form is sufficient)
2. Schedule a phone interview for after you have completed the test
and provide your mailing address.
3. Receive an at home SpermCheck® test via US postal service.
4. Complete the SpermCheck® test according to the instructions
included in the box.
5. Take part in a 15-minute phone interview with the primary
investigator. This interview will be recored in order to ensure the
details that you provide about your testing experience are
accurately captured.
DURATION:
Participation in the study involves using an at home SpermCheck® test and
then participating in a phone interview that is expected to last about 15
minutes.

RISKS/DISCOMFORTS:
There is a chance that taking this test and hearing these questions during the
phone interview may make you feel unexpected emotions. Additionally,
learning that there is or is not sperm present in the ejaculate may cause you
to feel unexpected emotions.
There is the risk of a breach of confidentiality, despite the steps that will be
taken to protect your identity. Specific safeguards to protect confidentiality are
described in a separate section of this document.

BENEFITS:
You may benefit from participating in this study by receiving a free
SpermCheck® test kit.
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COSTS:
There will be no costs to you for participating in this study.

PAYMENT TO PARTICIPANTS:
You will not be paid for participating in this part of this study.

CONFIDENTIALITY OF RECORDS:
Information obtained about you during this research may be published, but
you will not be identified. Information that is obtained concerning this research
that can be identified with you will remain confidential to the extent possible
within State and Federal law. The investigators associated with this study, the
sponsor, and the Institutional Review Board will have access to identifying
information. All records in South Carolina are subject to subpoena by a court
of law. Study information will be securely stored on password-protected
computers.

VOLUNTARY PARTICIPATION:
Participation in this research study is voluntary. You are free not to
participate, or to stop participating at any time, for any reason without
negative consequences. In the event that you do withdraw from this study,
the information you have already provided will be kept in a confidential
manner. If you wish to withdraw from the study, please call or email the
principal investigator listed on this form.

I have been given a chance to ask questions about this research study.
These questions have been answered to my satisfaction. If I have any more
questions about my participation in this study, or a study related injury,
I am to contact Allison Perez Szczepanski at (XXX) XXX-XXXX or email
allison.perez@uscmed.sc.edu.

Concerns about your rights as a research subject are to be directed to, Lisa
Johnson, Assistant Director, Office of Research Compliance, University of
South Carolina, 1600 Hampton Street, Suite 414D, Columbia, SC 29208,
phone: (803) 777-6670 or email: LisaJ@mailbox.sc.edu.
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I agree to participate in this study. I have been given a copy of this form for
my own records.

If you wish to participate, you should sign below.

Signature of Subject / Participant

Date

Signature of Qualified Person Obtaining Consent

Date
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APPENDIX F
SCHEDULING PHONE CALL SCRIPT
Hello, my name is Allison Perez Szczepanski. Am I speaking with [NAME
PROVIDED BY PARTICIPANT]?
Yes: *continue on*
No: Do you know when he may be available for a phone call? *Plan to call
back at that time*
I am calling to let you know that I received your signed consent form for the
second part of my study for Men with Cystic Fibrosis. Do you agree to this being
recorded?
Yes: *continue on*
No: Thank you for your time.
Do you still wish to participate in this research?
Yes: *continue on*
No: Thank you for your time.
In that case, I will need your mailing address so that I can send the testing kit to
you. What is your mailing address?
*Participant provides mailing address*
We will now schedule a time that we can speak after you complete the kit. The
timing of the sample is important in providing the most reliable results from the
home sperm test. Abstinence from ejaculation for at least 48 hours before taking
the test is required for the test to work, but there must be ejaculation occurring
within at least 7 days before the test. With that in mind, what days and times in
the coming weeks would work well for your schedule. I would like to speak with
you no more than 2 days after you complete the test.
*Schedule a time*
I look forward to speaking with you then. If you have any questions, please do
not hesitate to reach out to me. Thank you for your time.
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APPENDIX G
EMAIL INCLUIDNG MOCK SCHEDULE
Hello [PARTICIPANT NAME],
Below is a calendar for your testing schedule and a brief overview of instructions
for completing the test kit. I have also attached some directions from the testing
company.
Sun
1/**

Mon
1/**

Tues
1/**

Wed
1/**

Thurs
1/**

Fri
1/**
Call to
schedule
interview
1/**
1/**
1/**
1/**
1/**
1/**
No
No
Test
Phone
Ejaculation Ejaculation estimated interview
to arrive. at 5:00
Complete PM
test.
Instructions at a glance:

Sat
1/**

1/**

1.

Wait at least 2 days (but not more than 7 days) since last ejaculation

2.

Ejaculate into the cup provided in the test kit- it is important to collect all of
the ejaculation in the cup

3.

Wait 20 minutes

4.

Stir liquid with transfer device included with kit

5.

Transfer the specified volume (fill the dropper to the frosted line) of liquid
into the bottle with the purple top

6.

Turn the bottle upside down 5 to 10 times

7.

Wait 2 minutes

8.

Put exactly 6 drops of the liquid in the bottle onto the SpermCheck device

9.

Wait 7 minutes

10.

Read results
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I look forward to speaking with you next Friday. Please contact me with any
questions or concerns.
Best,

Allison Szczepanski
Genetic Counseling Candidate
University of South Carolina
School of Medicine
allison.perez@uscmed.sc.edu
(XXX) XXX-XXXX

96

APPENDIX H
SpermCheck® INSTRUCTIONS
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Figure H.1 SpermCheck® Instructions
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APPENDIX I
INTERVIEW PHONE CALL SCRIPT
Hello, this is Allison Perez Szczepanski. Am I speaking with [NAME PROVIDED
BY PARICIPANT]?
Yes: *Continue on*
No: Do you know when he may be available for a phone call? *Plan to call
back at that time*
I am calling for our scheduled phone interview regarding your participation in my
research study for men with Cystic Fibrosis. Is now still a good time to talk for
about 15 minutes?
Yes: Great
No: Have you completed your SpermCheck® fertility test kit?
Yes: When would be a better time for this phone call?
No: Do you still plan to complete the kit and participate in the phone
interview?
Yes: *reschedule time*
No: Thank you for your participation in my study.
Have you completed your SpermCheck® fertility test kit?
Yes: As a reminder, this call is being recorded. I will delete this recording after
our conversation is transcribed. Everything you say will be de-identified. You are
able to opt out at any time, end the interview, or chose not to answer any
question. This is completely voluntary. *Participant agrees*
No: Do you still plan to complete the kit and participate in the phone interview?
Yes: *reschedule time*
No: Thank you for your participation in my study.
If you have any questions about the fertility test you have completed, you can ask
me any questions at any time, including after the completion of this study, or
review your results with a health care provider.
I understand that the results of this test may have caused you to feel unexpected
or negative emotions. If you would like to discuss these before we begin the
interview, I am here to listen. I can answer any of your questions about the test
and your results to the best of my abilities and I would be happy to help you in
anyway I can. Is there anything you would like to share before we begin?
I have several questions to ask you, most of which are simple yes or no
questions. If you need clarification at any time, please ask me.
Were the directions that came with the kit easy to follow? Yes or no.
99

No: please explain.
The results of the test could be: two lines indicating a typical sperm count, one
line indicating a low sperm count, or no lines indicating an invalid test. What were
your SpermCheck® fertility test results? Two lines, one line, or no lines?
Did you get the results you were expecting based on prior understanding?
No: How were your results different from what you expected?
Do you believe that these results are accurate? Yes or no.
Have you undergone previous fertility testing? Yes or no.
Yes: Do these results agree with your previous fertility testing? Yes or no.
In light of your results using this kit, do you believe the counseling about fertility
in men with CF you previously received was accurate? Yes or no.
In part one of this study, you indicated that you would like to have
*PARTICIPANTS ANSWER TO QUESTION 30 ON SURVEY (this question is
about how many children they would like to have in the future- biological, donor
conceived, adopted, step, and total number)*. Have these results changed your
thoughts or goals for family planning? Yes or no.
Yes: In what ways?
Do you feel that the results of this test will change your birth control practices?
Yes or no.
Yes: In what ways?
Do you feel that the results of this test have changed your outlook on your
fertility? Yes or no.
Yes: In what ways?
Do you think access to this sort of test would be helpful to the CF community?
Yes or no.
Are there other comments about your experience that you would like to share?
This concludes the phone interview. I appreciate your time in participating in my
study. If you have any questions about this study in the future, please feel free to
contact me.
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